Summary
EudraCT Number: 2008-006265-93
Sponsor's Protocol Code Number: AVO1
National Competent Authority: Sweden - MPA 
Clinical Trial Type: EEA CTA
Trial Status: Ongoing
Date on which this record was first entered in the EudraCT database: 2008-10-23
Link: https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006265-93/SE/

A. Protocol Information
A.1 Member State Concerned: Sweden - MPA
A.2 EudraCT number: 2008-006265-93
A.3 Full title of the trial: A prospective, randomized, masked and controlled trial of intravitreal bevacizumab (Avastin®) for central retinal vein occlusion (CRVO). 
A.4.1 Sponsor's protocol code number: AVO1
A.7 Trial is part of a Paediatric Investigation Plan: Information not present in EudraCT
A.8 EMA Decision number of Paediatric Investigation Plan: 

B. Sponsor Information
Sponsor 1
B.1.1 Name of Sponsor: St Eriks Eye Hospital
B.1.3.4	Country: Sweden
B.3.1 and B.3.2	Status of the sponsor: Non-Commercial
B.4 Source(s) of Monetary or Material Support for the clinical trial:
B.4.1 Name of organisation providing support:
B.4.2 Country:
B.5 Contact point designated by the sponsor for further information on the trial
B.5.1 Name of organisation: 
B.5.2 Functional name of contact point: 

D. IMP Identification
D.IMP: 1
D.1.2 and D.1.3 IMP Role: Test
D.2 Status of the IMP to be used in the clinical trial
D.2.1 IMP to be used in the trial has a marketing authorisation: Yes
D.2.1.1.1 Trade name: Avastin ®  
D.2.1.1.2 Name of the Marketing Authorisation holder: F. Hoffmann-La Roche Ltd
D.2.1.2 Country which granted the Marketing Authorisation: Sweden
D.2.5 The IMP has been designated in this indication as an orphan drug in the Community: No
D.2.5.1 Orphan drug designation number: 
D.3 Description of the IMP
D.3.1 Product name: Avastin®
D.3.4 Pharmaceutical form: Injection*
D.3.4.1 Specific paediatric formulation: Information not present in EudraCT
D.3.7 Routes of administration for this IMP:
Intravitreal use
Ophthalmic use (Noncurrent)
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8 INN - Proposed INN: Bevacizumab
D.3.9.3 Other descriptive name: BEVACIZUMABUM
D.3.11 The IMP contains an
D.3.11.1 Active substance of chemical origin: No
D.3.11.2 Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP): Yes
D.3.11.3 Advanced Therapy IMP (ATIMP): Information not present in EudraCT
D.3.11.3.1 Somatic cell therapy medicinal product: No
D.3.11.3.2 Gene therapy medical product: No
D.3.11.3.3 Tissue Engineered Product: Information not present in EudraCT
D.3.11.3.4 Combination ATIMP (i.e. one involving a medical device): Information not present in EudraCT
D.3.11.3.5 Committee on Advanced therapies (CAT) has issued a classification for this product: Information not present in EudraCT
D.3.11.4 Combination product that includes a device, but does not involve an Advanced Therapy: Information not present in EudraCT
D.3.11.5 Radiopharmaceutical medicinal product: No
D.3.11.6 Immunological medicinal product (such as vaccine, allergen, immune serum): Yes
D.3.11.7 Plasma derived medicinal product: No
D.3.11.8 Extractive medicinal product: No
D.3.11.9 Recombinant medicinal product: Information not present in EudraCT
D.3.11.10 Medicinal product containing genetically modified organisms: No
D.3.11.11 Herbal medicinal product: No
D.3.11.12 Homeopathic medicinal product: No
D.3.11.13 Another type of medicinal product: Information not present in EudraCT

D.8 Information on Placebo

E. General Information on the Trial
E.1 Medical condition or disease under investigation
E.1.1 Medical condition(s) being investigated: Central retinal vein occlusion (CRVO) is a sight-threatening ocular condition without efficient treatment. 
MedDRA Classification
E.1.3 Condition being studied is a rare disease: No
E.2 Objective of the trial
E.2.1 Main objective of the trial: To study whether intravitreal bevacizumab (Avastin®) results in significant visual improvement in patients with CRVO as compared to the natural course of the disease.  
E.2.2 Secondary objectives of the trial: To study whether intravitreal bevacizumab (Avastin®) results in significantly decreased macular edema, reduced laser scatter treatments and decreased iris rubeosis in patients with CRVO as compared to the natural course of the disease.  
E.2.3 Trial contains a sub-study: No
E.3 Principal inclusion criteria: CRVO with a duration of 6 months or less. Visual acuity between 0.025-0.4 Snellen (5-67 ETDRS letters). 
E.4 Principal exclusion criteria: Previous CRVO treatment in study eye. Duration > 6 months. Previous treatment in study eye with anti-VEGF agents. 
E.5 End points
E.5.1 Primary end point(s): The proportion of patients gaining 15 ETDRS letters or more after 6 months.
E.6 and E.7 Scope of the trial
E.6 Scope of the Trial
E.6.1 Diagnosis: Information not present in EudraCT
E.6.2 Prophylaxis: Information not present in EudraCT
E.6.3 Therapy: Yes
E.6.4 Safety: Yes
E.6.5 Efficacy: Yes
E.6.6 Pharmacokinetic: Information not present in EudraCT
E.6.7 Pharmacodynamic: Information not present in EudraCT
E.6.8 Bioequivalence: Information not present in EudraCT
E.6.9 Dose response: Information not present in EudraCT
E.6.10 Pharmacogenetic: Information not present in EudraCT
E.6.11 Pharmacogenomic: Information not present in EudraCT
E.6.12 Pharmacoeconomic: Information not present in EudraCT
E.6.13 Others: Information not present in EudraCT
E.7 Trial type and phase 
E.7.1 Human pharmacology (Phase I): No
E.7.1.1 First administration to humans: No
E.7.1.2 Bioequivalence study: No
E.7.1.3 Other: No
E.7.1.3.1 Other trial type description: 
E.7.2 Therapeutic exploratory (Phase II): Yes
E.7.3 Therapeutic confirmatory (Phase III): No
E.7.4 Therapeutic use (Phase IV): No
E.8 Design of the trial
E.8.1 Controlled: Yes
E.8.1.1 Randomised: Yes
E.8.1.2 Open: No
E.8.1.3 Single blind: No
E.8.1.4 Double blind: Yes
E.8.1.5 Parallel group: No
E.8.1.6 Cross over: No
E.8.1.7 Other: No
E.8.2 Comparator of controlled trial
E.8.2.1 Other medicinal product(s): Information not present in EudraCT
E.8.2.2 Placebo: Information not present in EudraCT
E.8.2.3 Other: No
E.8.2.3.1 Comparator description: Sham injection
E.8.3 The trial involves single site in the Member State concerned: Yes
E.8.4 The trial involves multiple sites in the Member State concerned: No
E.8.5 The trial involves multiple Member States: No
E.8.6 Trial involving sites outside the EEA
E.8.6.1 Trial being conducted both within and outside the EEA: No
E.8.6.2 Trial being conducted completely outside of the EEA: Information not present in EudraCT
E.8.7 Trial has a data monitoring committee: Yes
E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial: 6 months analysis. 
E.8.9 Initial estimate of the duration of the trial
E.8.9.1 In the Member State concerned years: 
E.8.9.1 In the Member State concerned months: 6
E.8.9.1 In the Member State concerned days: 

F. Population of Trial Subjects
F.1 Age Range
F.1.1 Trial has subjects under 18: No
F.1.1.1 In Utero: Information not present in EudraCT
F.1.1.2 Preterm newborn infants (up to gestational age < 37 weeks): Information not present in EudraCT
F.1.1.3 Newborns (0-27 days): Information not present in EudraCT
F.1.1.4 Infants and toddlers (28 days-23 months): Information not present in EudraCT
F.1.1.5 Children (2-11years): Information not present in EudraCT
F.1.1.6 Adolescents (12-17 years): Information not present in EudraCT
F.1.2 Adults (18-64 years): Yes
F.1.3 Elderly (>=65 years): Yes
F.2 Gender
F.2.1 Female: Yes
F.2.2 Male: Yes
F.3 Group of trial subjects
F.3.1 Healthy volunteers: No
F.3.2 Patients: Yes
F.3.3 Specific vulnerable populations: No
F.3.3.1 Women of childbearing potential not using contraception : No
F.3.3.2 Women of child-bearing potential using contraception: No
F.3.3.3 Pregnant women: No
F.3.3.4 Nursing women: No
F.3.3.5 Emergency situation: No
F.3.3.6 Subjects incapable of giving consent personally: No
F.3.3.7 Others: No
F.4 Planned number of subjects to be included
F.4.1 In the member state: 60
F.4.2 For a multinational trial
F.4.2.2 In the whole clinical trial: 60
F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition): All patients will be offered intravitreal Avastin® if there is a significant difference between treatment groups.  

G. Investigator Networks to be involved in the Trial


N. Review by the Competent Authority or Ethics Committee in the country concerned
N. Competent Authority Decision: Authorised
N. Date of Competent Authority Decision: 2008-12-11
N. Ethics Committee Opinion of the trial application: Favourable
N. Ethics Committee Opinion: Reason(s) for unfavourable opinion:
N. Date of Ethics Committee Opinion: 2009-03-11

P. End of Trial
P. End of Trial Status: Ongoing

